相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Rudy Birsen et al.
HAEMATOLOGICA (2022)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
Jolanda Magri et al.
CELLS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Thomas Cluzeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer
Roberto Ruiu et al.
CANCERS (2021)
SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Kenji M. Fujihara et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelody-splastic syndromes and acute myeloid leukemia
Nabih Maslah et al.
HAEMATOLOGICA (2020)
Breast cancer stem cell antigens as targets for immunotherapy
Elena Quaglino et al.
SEMINARS IN IMMUNOLOGY (2020)
Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer
Laura Conti et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
Valeria Rolih et al.
CANCERS (2020)
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Ashkan Shahbandi et al.
TRENDS IN CANCER (2020)
Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter
Roberto Ruiu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Hideaki Ogiwara et al.
CANCER CELL (2019)
Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53
Yufei Wang et al.
EMBO REPORTS (2019)
Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
Michael D. Arensman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model
Yan Zhang et al.
CELL CHEMICAL BIOLOGY (2019)
A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
Elisabetta Bolli et al.
ONCOIMMUNOLOGY (2018)
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Michael J. Duffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma
Liang Zhang et al.
FUTURE ONCOLOGY (2018)
xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression
Xiangming Ji et al.
ONCOGENE (2018)
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
Kamil Lisek et al.
Oncotarget (2018)
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Naoise C. Synnott et al.
TRANSLATIONAL ONCOLOGY (2018)
Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
Lena Haffo et al.
SCIENTIFIC REPORTS (2018)
Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells
Gaetano Donofrio et al.
ONCOIMMUNOLOGY (2018)
Overexpression of cysteine-glutamate transporter and CD44 for prediction of recurrence and survival in patients with oral cavity squamous cell carcinoma
Jae Ryung Lee et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants
Sara Ibrahim Omar et al.
Oncotarget (2018)
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N. C. Synnott et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells
Emmanuel Dornier et al.
NATURE COMMUNICATIONS (2017)
NK cells control breast cancer and related cancer stem cell hematological spread
Rossana Tallerico et al.
ONCOIMMUNOLOGY (2017)
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
Anne Perdrix et al.
CANCERS (2017)
Administering xCT Inhibitors Based on Circadian Clock Improves Antitumor Effects
Fumiyasu Okazaki et al.
CANCER RESEARCH (2017)
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Brent R. Stockwell et al.
CELL (2017)
Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer
Stefania Lanzardo et al.
CANCER RESEARCH (2016)
PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells
Nobuhisa Yoshikawa et al.
ONCOLOGY REPORTS (2016)
An open-label phase I dose-finding study of APR-246 in hematological malignancies
S. Deneberg et al.
BLOOD CANCER JOURNAL (2016)
Targeting cancer stem cells with p53 modulators
Zhan Zhang et al.
ONCOTARGET (2016)
Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells
S. Geninatti Crich et al.
NANOSCALE (2015)
Ferroptosis as a p53-mediated activity during tumour suppression
Le Jiang et al.
NATURE (2015)
Antitumor immunization of mothers delays tumor development in cancer-prone offspring
Giuseppina Barutello et al.
ONCOIMMUNOLOGY (2015)
Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis
Scott J. Dixon et al.
ELIFE (2014)
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
Luika A. Timmerman et al.
CANCER CELL (2013)
The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells
Laura Conti et al.
FASEB JOURNAL (2013)
Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma
Hiroki Kinoshita et al.
ONCOLOGY REPORTS (2013)
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon et al.
CELL (2012)
Enhanced expression of cystine/glutamate transporter in the lung caused by the oxidative-stress-inducing agent paraquat
Sho Kobayashi et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma
Weijie Guo et al.
CANCER LETTERS (2011)
Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity
Victoria Linares et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
Pierre A. Robe et al.
BMC CANCER (2009)
The x c - cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine
Jun Guan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-κB
W. Joon Chung et al.
JOURNAL OF NEUROCHEMISTRY (2009)
IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing
G. Regis et al.
LEUKEMIA (2009)
Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy
Daniel W. Doxsee et al.
PROSTATE (2007)
Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells
Kyunghee Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses
HX Sang et al.
CANCER GENE THERAPY (2005)
分享论文
